Is BVS or GLUE more profitable?

BVS runs the higher net margin — BVS at 9.36% versus GLUE at -560.85%.

How have BVS and GLUE total returns compared?

Over the past 5 years, BVS delivered -0.81% and GLUE delivered -12.32% annualized total return. Past performance doesn't predict future results.

Bioventus Inc. (BVS) vs Monte Rosa Therapeutics, Inc. (GLUE)

A side-by-side comparison of Bioventus Inc. and Monte Rosa Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BVS

Bioventus Inc.

$894M

$13.19HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT

GLUE

Monte Rosa Therapeutics, Inc.

$866M

$10.25HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT

Total return — BVS vs GLUE

growth of $100 · dividends reinvested · last 5y

BVS -25.1% (-5.6%/yr)GLUE -51.5% (-13.5%/yr)BVS compounded faster over this window

BVS GLUE

BVS vs GLUE: by the numbers

•BVS is the larger company ($894M vs $866M market cap).
•BVS is profitable (9.36% net margin) while GLUE runs a net loss (-560.85%).

Metrics side by side

Valuation

Metric	BVS	GLUE
P/E ratio	17.13	N/A
Forward P/E	16.94	N/A
P/S ratio	1.54	30.15
P/B ratio	3.92	1.78
EV / EBITDA	10.54	N/A
FCF yield	10.55%	N/A

Profitability

Metric	BVS	GLUE
Gross margin	68.00%	92.94%
Operating margin	10.63%	-43.83%
Net margin	9.36%	-560.85%
ROE	23.86%	-33.06%
ROIC	11.37%	-28.69%

Growth (annualized)

Metric	BVS	GLUE
Revenue CAGR (5Y)	11.82%	N/A
EPS CAGR (5Y)	-5.03%	N/A
FCF CAGR (5Y)	43.36%	N/A
Total return CAGR (5Y)	-0.81%	-12.32%

Frequently asked

Is BVS or GLUE more profitable?: BVS runs the higher net margin — BVS at 9.36% versus GLUE at -560.85%.
How have BVS and GLUE total returns compared?: Over the past 5 years, BVS delivered -0.81% and GLUE delivered -12.32% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BVS analysis Full GLUE analysis Interactive comparison tool

Dig into the metrics

Bioventus P/E ratio Bioventus ROE Monte Rosa Therapeutics ROE Bioventus operating margin Monte Rosa Therapeutics operating margin Bioventus revenue growth Monte Rosa Therapeutics revenue growth Bioventus free cash flow Monte Rosa Therapeutics free cash flow

Bioventus & Monte Rosa Therapeutics appear in these rankings

Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.